Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 3454

Next Previous
Drug Profile

TQB 3454

Alternative Names: TQB-3454

Latest Information Update: 29 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 29 Nov 2023 TQB 3454 is still in phase I trials for Haematological malignancies (First-line therapy, In adults, In the elderly, Late-stage disease) and Solid tumours (First-line therapy, In adults, In the elderly, Late-stage disease) in China (PO) (NCT04481607)
  • 18 Nov 2023 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial In volunteers in China (PO) in November 2023 (NCT06139367)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Haematological-malignancies (First-line therapy, In the elderly, Late-stage disease, In adults) in China (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top